STAGE IIIC LUNG CANCER AJCC V8

This early-phase study tests a new combination of two drugs, minnelide and osimertinib, for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). The main goal is to find the safest dose and see how the body responds. Only 8 participants…

This early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer that has spread or come back. The goal is to find the safest dose of the targeted drug ensartinib when given with standard chemotherapy (carboplatin, pemetrexed) a…

This study tests a vaccine called CIMAvax combined with immunotherapy drugs (nivolumab or pembrolizumab) in people with advanced non-small cell lung cancer or head/neck cancer that has spread. The goal is to find the best dose and see if the combination helps control tumor growth…

This study is for people with advanced non-small cell lung cancer that has come back or spread. It tests a combination of two drugs: trametinib, which blocks cancer cell growth, and pembrolizumab, which helps the immune system attack cancer. The goal is to see if this combination…

This study tests whether a cancer drug called atezolizumab can be given safely at home to people with non-small cell lung cancer. Instead of going to a clinic, patients receive the injection under the skin from a nurse while using telemedicine. The goal is to see if this home-bas…

This study tests a new drug (aurora kinase inhibitor) combined with a standard targeted therapy (osimertinib) for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see if the combination can better control tumor growth. About 32 …

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemotherapy) can help people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV disease will be randomly assigned to r…

This early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. Researchers are testing a combination of two drugs—brigatinib and bevacizumab—to see what dose is …

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that responded to initial chemotherapy. The goal is to find the safest dose and see if the combo helps keep can…

This phase 3 trial studies the best way to use immunotherapy (pembrolizumab) and chemotherapy for advanced non-squamous non-small cell lung cancer. About 600 participants receive either immunotherapy alone first, then chemo with or without immunotherapy later, or a combination of…

This early-phase trial is testing whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this approach ca…

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…

This early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…

This study compares two treatments for lung tumors: microwave ablation (using heat to kill cancer cells) and surgical wedge resection (removing a small piece of lung). It includes people with early or advanced lung cancer, sarcoma, or colorectal cancer that has spread to the lung…

This study tests whether combining two drugs—niraparib (which blocks cancer cells from repairing themselves) and dostarlimab (which helps the immune system attack cancer)—can control small cell lung cancer and other high-grade neuroendocrine carcinomas. About 48 adults whose canc…

This early-phase study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be removed by surgery. The main goals are to find the safest dose…

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation (and continuing it afterward) helps people with stage 3 lung cancer that can't be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagnosed…

This study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced non-small cell lung cancer who have lost their appetite and weight. About 25 participants will take either the drug or a placebo and share their experiences…

This study tests an online program designed to improve social well-being and emotional support for women being treated for lung cancer. About 70 women with stage I to IV non-small cell lung cancer will take part. The program uses mindfulness and emotional processing techniques to…

This study looks at whether giving a single, precise dose of radiation after lung cancer surgery is safe and causes fewer side effects than the usual weeks-long radiation. About 50 adults with non-small cell lung cancer who had surgery but still have cancer cells at the edge of t…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about the future. About 42 participants will try the program to see if it is practical and helpful in medical centers and clinics. The goal is to learn if this ap…

This study looks at over 1,300 cancer patients to find out who is more likely to develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track factors like age, gender, and pre-existing conditions to create a prediction tool. The g…

This study tests a telehealth self-management program for people who have finished treatment for early-stage lung or colorectal cancer. The program coaches survivors on follow-up care, communication with doctors, and managing their health. Researchers want to see if it improves c…